Longterm Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy



Status:Enrolling by invitation
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:Any - 50
Updated:2/2/2019
Start Date:September 2013
End Date:March 2031

Use our guide to learn which trials are right for you!

Longterm Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector

This is a multi-center, long-term safety and efficacy follow-up study for subjects with
hemoglobinopathies (β-thalassemia or severe sickle cell disease) who have been treated with
ex vivo gene therapy drug product in bluebird bio-sponsored clinical studies. After
completing the parent clinical study (approximately 2 years), eligible subjects will be
followed for an additional 13 years for a total of 15 years post-drug product infusion. No
investigational drug product will be administered in the study.


Inclusion Criteria:

- Provision of written informed consent for this study by subjects, or as applicable,
subject's parent(s)/legal guardian(s)

- Treated with drug product for therapy of a hemoglobinopathy in a bluebird
bio-sponsored clinical study

- Able to comply with study requirements

Exclusion Criteria:

- Met the VCN discontinuation criterion in the parent study
We found this trial at
6
sites
1331
mi
from
Oakland, CA
Click here to add this to my saved trials
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Charleston, South Carolina 29412
1064
mi
from
Charleston, SC
Click here to add this to my saved trials
610
mi
from
Chicago, IL
Click here to add this to my saved trials
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
8648
mi
from
Sydney,
Click here to add this to my saved trials